11-Day Breast Cancer Combo Offers Promise For Personalized Therapy
This article was originally published in Scrip
Executive Summary
A Cancer Research UK-funded study has shown that combination treatment of Tykerb (lapatinib; Novartis AG) and Herceptin (trastuzumab; Roche Holding AG), given before surgery, is able to shrink and "destroy" tumors in women with HER2-positive breast cancer within 11 days.